Eligible patients with FLT3-ITDhigh or FLT3-ITDlow NPM1 wildtype AML benefitted from an allogeneic HSCT [8], followed by post-transplant maintenance with sorafenib [9, 10]. This evidence concerns the gene FLT3 and acute myeloid leukemia.